A 16-week Randomized, Open-label, Multicenter Study to Assess the Superiority of Secukinumab Over Guselkumab in the Complete Treatment of Ustekinumab Resistant Psoriatic Plaques
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2018
At a glance
- Drugs Secukinumab (Primary) ; Guselkumab
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Acronyms ARROW
- Sponsors Novartis Pharmaceuticals
- 25 Oct 2018 Planned End Date changed from 8 Jul 2019 to 2 Aug 2019.
- 25 Oct 2018 Planned primary completion date changed from 8 Jul 2019 to 2 Aug 2019.
- 25 Oct 2018 Status changed from not yet recruiting to recruiting.